KR20240004691A

KR20240004691A - 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드

낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드 Download PDF

Info

Publication number: KR20240004691A
Authority: KR; South Korea
Prior art keywords: patient; ethyl; cyano; carboxamide; oxazepane
Prior art date: 2021-04-29
Legal status : Pending

Application number

KR1020237040988A

Other languages

English (en)

Korean (ko)

Inventor

헬렌 후이 우산스키

아리엘 테퍼

마르셀라 마르타 베르가라

안드레아 린 매스

Original Assignee

인스메드 인코포레이티드

Priority date

2021-04-29

Filing date

2022-04-29

Publication date

2024-01-11

2022-04-29 Application filed by 인스메드 인코포레이티드 filed Critical 인스메드 인코포레이티드

2024-01-11 Publication of KR20240004691A publication Critical patent/KR20240004691A/ko

Status Pending legal-status Critical Current

Links

201000003883 Cystic fibrosis Diseases 0.000 title claims abstract description 105
238000011282 treatment Methods 0.000 title claims description 63
NKLBVYYBRRBLAE-UHFFFAOYSA-N N-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamide Chemical compound N#CC(CC1=CC=CC=C1)NC(C1OCCCNC1)=O NKLBVYYBRRBLAE-UHFFFAOYSA-N 0.000 title 1
238000000034 method Methods 0.000 claims abstract description 267
239000000203 mixture Substances 0.000 claims abstract description 172
150000001875 compounds Chemical class 0.000 claims abstract description 160
AEXFXNFMSAAELR-RXVVDRJESA-N brensocatib Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 claims abstract description 139
229940010847 brensocatib Drugs 0.000 claims abstract description 132
150000003839 salts Chemical class 0.000 claims abstract description 109
230000004199 lung function Effects 0.000 claims abstract description 41
125000000217 alkyl group Chemical group 0.000 claims description 57
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 43
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 40
206010036790 Productive cough Diseases 0.000 claims description 38
239000008019 pharmaceutical lubricant Substances 0.000 claims description 38
210000003802 sputum Anatomy 0.000 claims description 38
208000024794 sputum Diseases 0.000 claims description 38
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
229940124630 bronchodilator Drugs 0.000 claims description 34
229910052717 sulfur Inorganic materials 0.000 claims description 33
229910052739 hydrogen Inorganic materials 0.000 claims description 32
239000001257 hydrogen Substances 0.000 claims description 32
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 30
210000000440 neutrophil Anatomy 0.000 claims description 30
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 29
229910052731 fluorine Inorganic materials 0.000 claims description 27
239000008024 pharmaceutical diluent Substances 0.000 claims description 25
208000035143 Bacterial infection Diseases 0.000 claims description 24
208000022362 bacterial infectious disease Diseases 0.000 claims description 24
229910052801 chlorine Inorganic materials 0.000 claims description 24
239000008194 pharmaceutical composition Substances 0.000 claims description 24
230000007423 decrease Effects 0.000 claims description 22
210000004072 lung Anatomy 0.000 claims description 21
108010028275 Leukocyte Elastase Proteins 0.000 claims description 20
102000016799 Leukocyte elastase Human genes 0.000 claims description 20
210000004369 blood Anatomy 0.000 claims description 20
239000008280 blood Substances 0.000 claims description 20
229910052760 oxygen Inorganic materials 0.000 claims description 20
230000002829 reductive effect Effects 0.000 claims description 20
-1 sulfa Chemical class 0.000 claims description 17
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 16
241000894006 Bacteria Species 0.000 claims description 16
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
239000008108 microcrystalline cellulose Substances 0.000 claims description 16
229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
239000000449 pharmaceutical disintegrant Substances 0.000 claims description 16
LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 15
102000004173 Cathepsin G Human genes 0.000 claims description 15
108090000617 Cathepsin G Proteins 0.000 claims description 15
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
230000003115 biocidal effect Effects 0.000 claims description 14
238000007906 compression Methods 0.000 claims description 13
230000006835 compression Effects 0.000 claims description 13
239000000377 silicon dioxide Substances 0.000 claims description 13
235000012239 silicon dioxide Nutrition 0.000 claims description 13
239000008109 sodium starch glycolate Substances 0.000 claims description 13
229940079832 sodium starch glycolate Drugs 0.000 claims description 13
229920003109 sodium starch glycolate Polymers 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 10
239000003242 anti bacterial agent Substances 0.000 claims description 9
230000001332 colony forming effect Effects 0.000 claims description 9
125000001424 substituent group Chemical group 0.000 claims description 9
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 8
102000035195 Peptidases Human genes 0.000 claims description 8
108091005804 Peptidases Proteins 0.000 claims description 8
229960003644 aztreonam Drugs 0.000 claims description 8
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 8
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
208000032536 Pseudomonas Infections Diseases 0.000 claims description 7
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 7
RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 claims description 7
229940108538 colistimethate Drugs 0.000 claims description 7
108700028201 colistinmethanesulfonic acid Proteins 0.000 claims description 7
230000003247 decreasing effect Effects 0.000 claims description 7
230000009325 pulmonary function Effects 0.000 claims description 7
230000000241 respiratory effect Effects 0.000 claims description 7
102000012479 Serine Proteases Human genes 0.000 claims description 6
108010022999 Serine Proteases Proteins 0.000 claims description 6
206010041925 Staphylococcal infections Diseases 0.000 claims description 6
AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
208000015339 staphylococcus aureus infection Diseases 0.000 claims description 6
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 5
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
125000003386 piperidinyl group Chemical group 0.000 claims description 5
229960000707 tobramycin Drugs 0.000 claims description 5
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 5
FCRODBUNBQJNPU-SFTDATJTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-cyanophenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)C#N)NC(=O)[C@H]1OCCCNC1 FCRODBUNBQJNPU-SFTDATJTSA-N 0.000 claims description 4
MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 claims description 4
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
229930182566 Gentamicin Natural products 0.000 claims description 4
MVRHVFSOIWFBTE-INIZCTEOSA-N N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide Chemical compound CN1N=C(C(=C1)S(=O)(=O)NC(=O)C=1C(=NC(=CC=1)N1N=C(C=C1)OCC(C(F)(F)F)(C)C)N1C(C[C@@H](C1)C)(C)C)C MVRHVFSOIWFBTE-INIZCTEOSA-N 0.000 claims description 4
229960004821 amikacin Drugs 0.000 claims description 4
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
229940012392 elexacaftor Drugs 0.000 claims description 4
229960002518 gentamicin Drugs 0.000 claims description 4
PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical group C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims description 4
229960004508 ivacaftor Drugs 0.000 claims description 4
UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims description 4
229960000998 lumacaftor Drugs 0.000 claims description 4
229950005823 tezacaftor Drugs 0.000 claims description 4
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 3
241001453380 Burkholderia Species 0.000 claims description 3
229930186147 Cephalosporin Natural products 0.000 claims description 3
208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 3
229930182555 Penicillin Natural products 0.000 claims description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
229930189077 Rifamycin Natural products 0.000 claims description 3
239000004098 Tetracycline Substances 0.000 claims description 3
108010059993 Vancomycin Proteins 0.000 claims description 3
229940126575 aminoglycoside Drugs 0.000 claims description 3
YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 3
229940124587 cephalosporin Drugs 0.000 claims description 3
150000001780 cephalosporins Chemical class 0.000 claims description 3
229960004287 clofazimine Drugs 0.000 claims description 3
WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 3
229960000285 ethambutol Drugs 0.000 claims description 3
239000003120 macrolide antibiotic agent Substances 0.000 claims description 3
229940049954 penicillin Drugs 0.000 claims description 3
235000019833 protease Nutrition 0.000 claims description 3
235000019364 tetracycline Nutrition 0.000 claims description 3
150000003522 tetracyclines Chemical class 0.000 claims description 3
229960003165 vancomycin Drugs 0.000 claims description 3
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
BQIZWZAQEICNDG-GMAHTHKFSA-N (2S)-N-[(1S)-1-cyano-2-[4-(1-methyl-2-oxoquinolin-7-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C2C=CC(N(C2=C1)C)=O)NC(=O)[C@H]1OCCCNC1 BQIZWZAQEICNDG-GMAHTHKFSA-N 0.000 claims description 2
WOBKXJRTDASPHQ-REWPJTCUSA-N (2S)-N-[(1S)-1-cyano-2-[4-(2-oxo-3-propan-2-yl-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C(C)C)C1)NC(=O)[C@H]1OCCCNC1 WOBKXJRTDASPHQ-REWPJTCUSA-N 0.000 claims description 2
SABYNPLHFAPZQF-RXVVDRJESA-N (2S)-N-[(1S)-1-cyano-2-[4-(3,3-difluoro-1-methyl-2-oxoindol-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C2C(C(N(C2=C1)C)=O)(F)F)NC(=O)[C@H]1OCCCNC1 SABYNPLHFAPZQF-RXVVDRJESA-N 0.000 claims description 2
WCWJGAFMGPMBQG-FPOVZHCZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3,7-dimethyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)C)C1)C)NC(=O)[C@H]1OCCCNC1 WCWJGAFMGPMBQG-FPOVZHCZSA-N 0.000 claims description 2
HZZYFVOLMKQYKP-UGKGYDQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-ethyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC)C1)NC(=O)[C@H]1OCCCNC1 HZZYFVOLMKQYKP-UGKGYDQZSA-N 0.000 claims description 2
ORHUZDNZRYZSJO-UNMCSNQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-ethyl-7-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)CC)C1)C)NC(=O)[C@H]1OCCCNC1 ORHUZDNZRYZSJO-UNMCSNQZSA-N 0.000 claims description 2
DRQDONWWFWYTII-ICSRJNTNSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzothiazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(S2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 DRQDONWWFWYTII-ICSRJNTNSA-N 0.000 claims description 2
PYXGGJVWIVBQRO-PMACEKPBSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-fluorophenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)F)NC(=O)[C@H]1OCCCNC1 PYXGGJVWIVBQRO-PMACEKPBSA-N 0.000 claims description 2
NSLGCWMFHWURGT-FPOVZHCZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-methyl-3-oxo-1,4-benzothiazin-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(CS2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 NSLGCWMFHWURGT-FPOVZHCZSA-N 0.000 claims description 2
QKDQSHLZLZUQOA-UGKGYDQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-methyl-3-oxo-1,4-benzoxazin-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(CO2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 QKDQSHLZLZUQOA-UGKGYDQZSA-N 0.000 claims description 2
IVHOZTBKWBUDMJ-PXNSSMCTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(7-fluoro-3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)C)C1)F)NC(=O)[C@H]1OCCCNC1 IVHOZTBKWBUDMJ-PXNSSMCTSA-N 0.000 claims description 2
KAGSLWGZQVTFPB-RXVVDRJESA-N (2S)-N-[(1S)-1-cyano-2-[4-[2-oxo-3-(2,2,2-trifluoroethyl)-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC(F)(F)F)C1)NC(=O)[C@H]1OCCCNC1 KAGSLWGZQVTFPB-RXVVDRJESA-N 0.000 claims description 2
PVRGXPYTNXSTMU-PXNSSMCTSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)CC(F)F)C1)F)NC(=O)[C@H]1OCCCNC1 PVRGXPYTNXSTMU-PXNSSMCTSA-N 0.000 claims description 2
LRDOUIXCGZNESR-REWPJTCUSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC(C)(C)O)C1)NC(=O)[C@H]1OCCCNC1 LRDOUIXCGZNESR-REWPJTCUSA-N 0.000 claims description 2
GRJJVLYWMJAVMA-UNMCSNQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-methoxyethyl)-2-oxo-1,3-benzothiazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(S2)=O)CCOC)C1)NC(=O)[C@H]1OCCCNC1 GRJJVLYWMJAVMA-UNMCSNQZSA-N 0.000 claims description 2
JUXOTDAODWSCQS-REWPJTCUSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-methoxyethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CCOC)C1)NC(=O)[C@H]1OCCCNC1 JUXOTDAODWSCQS-REWPJTCUSA-N 0.000 claims description 2
WJXGZWWSCFPECN-URXFXBBRSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(cyclopropylmethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC2CC2)C1)NC(=O)[C@H]1OCCCNC1 WJXGZWWSCFPECN-URXFXBBRSA-N 0.000 claims description 2
KFOHIWSKADTAQW-OZXSUGGESA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(oxan-4-ylmethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC2CCOCC2)C1)NC(=O)[C@H]1OCCCNC1 KFOHIWSKADTAQW-OZXSUGGESA-N 0.000 claims description 2
BVHRFMZXVRJZAF-URXFXBBRSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-[2-(dimethylamino)ethyl]-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CCN(C)C)C1)NC(=O)[C@H]1OCCCNC1 BVHRFMZXVRJZAF-URXFXBBRSA-N 0.000 claims description 2
MUTKXUKCDAFWLB-ICSRJNTNSA-N (2S)-N-[(1S)-2-[4-(1,3-benzothiazol-5-yl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound S1C=NC2=C1C=CC(=C2)C2=CC=C(C=C2)C[C@@H](C#N)NC(=O)[C@H]2OCCCNC2 MUTKXUKCDAFWLB-ICSRJNTNSA-N 0.000 claims description 2
GCGGEFOSHQPZEX-PXNSSMCTSA-N (2S)-N-[(1S)-2-[4-(4-carbamoyl-3-fluorophenyl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(N)(=O)C1=C(C=C(C=C1)C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)[C@H]1OCCCNC1)F GCGGEFOSHQPZEX-PXNSSMCTSA-N 0.000 claims description 2
KTGYWWMCWUTXTI-PXNSSMCTSA-N (2S)-N-[(1S)-2-[4-(7-chloro-3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound ClC1=CC(=CC=2N(C(OC21)=O)C)C2=CC=C(C=C2)C[C@@H](C#N)NC(=O)[C@H]2OCCCNC2 KTGYWWMCWUTXTI-PXNSSMCTSA-N 0.000 claims description 2
CBWWXOUBSQCMHB-GMAHTHKFSA-N (2S)-N-[(1S)-2-[4-[4-(azetidin-1-ylsulfonyl)phenyl]phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound N1(CCC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)[C@H]1OCCCNC1 CBWWXOUBSQCMHB-GMAHTHKFSA-N 0.000 claims description 2
206010061190 Haemophilus infection Diseases 0.000 claims description 2
206010054138 Stenotrophomonas infection Diseases 0.000 claims description 2
IRYUDRJLDSHZAO-FPOVZHCZSA-N [3-[4-[(2S)-2-cyano-2-[[(2S)-1,4-oxazepane-2-carbonyl]amino]ethyl]phenyl]phenyl] methanesulfonate Chemical compound CS(=O)(=O)OC=1C=C(C=CC1)C1=CC=C(C=C1)C[C@H](NC(=O)[C@H]1OCCCNC1)C#N IRYUDRJLDSHZAO-FPOVZHCZSA-N 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 9
241000020730 Burkholderia cepacia complex Species 0.000 claims 1
150000007660 quinolones Chemical class 0.000 claims 1
BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims 1
229940081192 rifamycins Drugs 0.000 claims 1
238000009492 tablet coating Methods 0.000 claims 1
239000002700 tablet coating Substances 0.000 claims 1
229940040944 tetracyclines Drugs 0.000 claims 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 16
101710087078 Dipeptidyl peptidase 1 Proteins 0.000 abstract description 14
102100029921 Dipeptidyl peptidase 1 Human genes 0.000 abstract description 14
235000002639 sodium chloride Nutrition 0.000 description 87
102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 33
238000013125 spirometry Methods 0.000 description 22
210000003622 mature neutrocyte Anatomy 0.000 description 17
229940068196 placebo Drugs 0.000 description 16
239000000902 placebo Substances 0.000 description 16
239000003826 tablet Substances 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
239000002552 dosage form Substances 0.000 description 15
239000003814 drug Substances 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
229940079593 drug Drugs 0.000 description 13
239000000090 biomarker Substances 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
238000011156 evaluation Methods 0.000 description 11
229960001866 silicon dioxide Drugs 0.000 description 11
238000012360 testing method Methods 0.000 description 11
229940049654 glyceryl behenate Drugs 0.000 description 10
239000008187 granular material Substances 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
239000000314 lubricant Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
208000019693 Lung disease Diseases 0.000 description 8
241000589517 Pseudomonas aeruginosa Species 0.000 description 8
239000007884 disintegrant Substances 0.000 description 8
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 8
230000004054 inflammatory process Effects 0.000 description 8
210000003097 mucus Anatomy 0.000 description 8
229940045902 sodium stearyl fumarate Drugs 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
102000003896 Myeloperoxidases Human genes 0.000 description 7
108090000235 Myeloperoxidases Proteins 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
235000011187 glycerol Nutrition 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
210000000130 stem cell Anatomy 0.000 description 7
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 6
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
239000008186 active pharmaceutical agent Substances 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 6
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
230000006872 improvement Effects 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
238000005259 measurement Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000000454 talc Substances 0.000 description 6
235000012222 talc Nutrition 0.000 description 6
229910052623 talc Inorganic materials 0.000 description 6
230000007704 transition Effects 0.000 description 6
229940098780 tribehenin Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
208000035752 Live birth Diseases 0.000 description 5
239000004365 Protease Substances 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical class CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
230000006870 function Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
238000000634 powder X-ray diffraction Methods 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
238000012552 review Methods 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000037396 body weight Effects 0.000 description 4
201000009267 bronchiectasis Diseases 0.000 description 4
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
239000008116 calcium stearate Substances 0.000 description 4
235000013539 calcium stearate Nutrition 0.000 description 4
229940078456 calcium stearate Drugs 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
210000000038 chest Anatomy 0.000 description 4
238000013461 design Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000036541 health Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000395 magnesium oxide Substances 0.000 description 4
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
235000012245 magnesium oxide Nutrition 0.000 description 4
239000000391 magnesium silicate Substances 0.000 description 4
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 4
239000008107 starch Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
208000032376 Lung infection Diseases 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
235000021314 Palmitic acid Nutrition 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004373 Pullulan Substances 0.000 description 3
229920001218 Pullulan Polymers 0.000 description 3
208000004756 Respiratory Insufficiency Diseases 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
241000191967 Staphylococcus aureus Species 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
101150014732 asnS gene Proteins 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
230000006020 chronic inflammation Effects 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000011262 co‐therapy Methods 0.000 description 3
239000013078 crystal Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000005713 exacerbation Effects 0.000 description 3
239000010408 film Substances 0.000 description 3
239000007941 film coated tablet Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000000732 glass refractive index measurement Methods 0.000 description 3
229940075507 glyceryl monostearate Drugs 0.000 description 3
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 3
229940046813 glyceryl palmitostearate Drugs 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
235000005772 leucine Nutrition 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229960000502 poloxamer Drugs 0.000 description 3
229920001983 poloxamer Polymers 0.000 description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
235000010235 potassium benzoate Nutrition 0.000 description 3
229940103091 potassium benzoate Drugs 0.000 description 3
239000004300 potassium benzoate Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
235000019423 pullulan Nutrition 0.000 description 3
230000005855 radiation Effects 0.000 description 3
201000004193 respiratory failure Diseases 0.000 description 3
230000028327 secretion Effects 0.000 description 3
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
235000010234 sodium benzoate Nutrition 0.000 description 3
239000004299 sodium benzoate Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108010078777 Colistin Proteins 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
206010011732 Cyst Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000003837 Epithelial Sodium Channels Human genes 0.000 description 2
108090000140 Epithelial Sodium Channels Proteins 0.000 description 2
239000004386 Erythritol Substances 0.000 description 2
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
229920001202 Inulin Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
101150094373 Padi4 gene Proteins 0.000 description 2
229920001100 Polydextrose Polymers 0.000 description 2
102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229940105329 carboxymethylcellulose Drugs 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960003346 colistin Drugs 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
208000031513 cyst Diseases 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
235000019414 erythritol Nutrition 0.000 description 2
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
229940009714 erythritol Drugs 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000028023 exocytosis Effects 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000008975 immunomodulatory function Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000002050 international nonproprietary name Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
229940029339 inulin Drugs 0.000 description 2
239000000905 isomalt Substances 0.000 description 2
235000010439 isomalt Nutrition 0.000 description 2
HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
239000000832 lactitol Substances 0.000 description 2
235000010448 lactitol Nutrition 0.000 description 2
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
229960003451 lactitol Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
229960000869 magnesium oxide Drugs 0.000 description 2
229910052919 magnesium silicate Inorganic materials 0.000 description 2
235000019792 magnesium silicate Nutrition 0.000 description 2
229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
235000019793 magnesium trisilicate Nutrition 0.000 description 2
229940099273 magnesium trisilicate Drugs 0.000 description 2
235000010449 maltitol Nutrition 0.000 description 2
239000000845 maltitol Substances 0.000 description 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
229940035436 maltitol Drugs 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000000420 mucociliary effect Effects 0.000 description 2
210000001167 myeloblast Anatomy 0.000 description 2
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
239000007935 oral tablet Substances 0.000 description 2
229940096978 oral tablet Drugs 0.000 description 2
239000006191 orally-disintegrating tablet Substances 0.000 description 2
230000036284 oxygen consumption Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
235000013856 polydextrose Nutrition 0.000 description 2
239000001259 polydextrose Substances 0.000 description 2
229940035035 polydextrose Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
239000000047 product Substances 0.000 description 2
235000019419 proteases Nutrition 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229960003292 rifamycin Drugs 0.000 description 2
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229940083037 simethicone Drugs 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229940001593 sodium carbonate Drugs 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229960002668 sodium chloride Drugs 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
229940074410 trehalose Drugs 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
ANPJTTUBCRFBKA-RXVVDRJESA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2,2-difluoroethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC(F)F)C1)NC(=O)[C@H]1OCCCNC1 ANPJTTUBCRFBKA-RXVVDRJESA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical group C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241001673062 Achromobacter xylosoxidans Species 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
102000008096 B7-H1 Antigen Human genes 0.000 description 1
108010074708 B7-H1 Antigen Proteins 0.000 description 1
206010069657 Burkholderia cepacia complex infection Diseases 0.000 description 1
102100025222 CD63 antigen Human genes 0.000 description 1
101150029409 CFTR gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
102100033636 Histone H3.2 Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100026236 Interleukin-8 Human genes 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 1
241001508003 Mycobacterium abscessus Species 0.000 description 1
241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
102000004722 NADPH Oxidases Human genes 0.000 description 1
108010002998 NADPH Oxidases Proteins 0.000 description 1
206010029379 Neutrophilia Diseases 0.000 description 1
108010064719 Oxyhemoglobins Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
101150058068 SLC2A1 gene Proteins 0.000 description 1
241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
210000005058 airway cell Anatomy 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
101150088826 arg1 gene Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000004630 atomic force microscopy Methods 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
229940116224 behenate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
229940127214 bronchodilator medication Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
235000010410 calcium alginate Nutrition 0.000 description 1
239000000648 calcium alginate Substances 0.000 description 1
229960002681 calcium alginate Drugs 0.000 description 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000006329 citrullination Effects 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
125000004431 deuterium atom Chemical group 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
210000003499 exocrine gland Anatomy 0.000 description 1
230000006539 extracellular acidification Effects 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000000477 gelanolytic effect Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
102000055276 human IL3 Human genes 0.000 description 1
102000055151 human KITLG Human genes 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000005931 immune cell recruitment Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000010569 immunofluorescence imaging Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229940125369 inhaled corticosteroids Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
231100000516 lung damage Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229960001708 magnesium carbonate Drugs 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229960002160 maltose Drugs 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
238000012335 pathological evaluation Methods 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
210000000680 phagosome Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000009613 pulmonary function test Methods 0.000 description 1
238000002106 pulse oximetry Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229940080350 sodium stearate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012306 spectroscopic technique Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
230000009182 swimming Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000010409 thin film Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1